Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 11/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3109493 | 0.85 | BDKRB1 (0.61) | BDKRB1SLC6A3SLC6A4ACHEKDM4E | |
| SCHEMBL5782374 | 0.84 | BDKRB1 (0.60) | BDKRB1SLC6A3SLC6A4ACHEKDM4E | |
| SCHEMBL5782255 | 0.84 | BDKRB1 (0.66) | BDKRB1SLC6A3SLC6A4ACHE | |
| SCHEMBL5782458 | 0.83 | BDKRB1 (0.65) | BDKRB1SLC6A3SLC6A4 | |
| SCHEMBL2338182 | 0.81 | BDKRB1 (1.00) | BDKRB1SLC6A3SLC6A4ACHEALDH1A1 | |
| SCHEMBL3264766 | 0.78 | BDKRB1 (0.53) | BDKRB1SLC6A3SLC6A4KDM4EALDH1A1 | |
| SCHEMBL2782748 | 0.78 | CHRNB2 (0.59) | BDKRB1SLC6A3SLC6A4CHRNB2CHRNB4 | |
| SCHEMBL5061628 | 0.77 | SLC6A3 (0.61) | BDKRB1SLC6A3SLC6A4KDM4EALDH1A1 | |
| SCHEMBL5924515 | 0.77 | SLC6A3 (0.55) | BDKRB1SLC6A3SLC6A4KDM4EALDH1A1 | |
| SCHEMBL3112718 | 0.76 | SLC6A3 (0.69) | BDKRB1SLC6A3SLC6A4KDM4ESLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091380-B2 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1476419-B1 | N-BIPHENYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | MERCK & CO INC (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050085667-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives | MERCK SHARP & DOHME LLC | 2005-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085667-A1 | N-biphenylmethyl aminocycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, LTB4R2 | BDKRB1 1/4885SLC6A3 3890/4885SLC6A4 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.